Compare Adaptive Biotechnologies Corp (ADPT) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Canadian National Railway Co. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Canadian National Railway Co. trades at $122.84 (market cap $74.49B). The key difference: Canadian National Railway Co. is far larger — about 22.4× Adaptive Biotechnologies Corp's market cap, and Canadian National Railway Co. pays a 2.1% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CNI | |
|---|---|---|
Market Cap | $3.33B | $74.49B |
Sector | Health | Industrials |
52-Week High | $22.37 | $122.78 |
52-Week Low | $10.24 | $90.91 |
Enterprise Value | $3.19B | $89.95B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CNI trades at $122.78, up 1.0% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS in line with expectations at $1.31, following beats in prior quarters, and maintains strong profitability with a 27.23% net income margin. Recent news highlights operational records in propane and grain shipments, alongside a new rail agreement for BHP's Jansen Potash Mine, supporting long-term growth.
The outlook is positive with a consensus price target of $142.33 implying 16% upside, though high valuation multiples and rising debt levels pose risks. Analyst sentiment is mixed with 35% buy ratings, but institutional interest remains steady. Key catalysts include Q2 2026 earnings on July 24, 2026, and execution on new logistics contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
